[Potentiation of the resistance to viral and bacterial infections after pidotimod administration in mice].
Marelli
P
P
Dipartimento di Biomedicina Sperimentale, Infettiva e Pubblica, Università degli Studi di Pisa, Italia.
Lupetti
A
A
Senesi
S
S
Uslenghi
C
C
Girardello
R
R
Campa
M
M
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001424:Bacterial Infections / Q000276:immunology / Q000517:prevention & control*; D003384:Coxsackievirus Infections / Q000276:immunology / Q000473:pathology; D029822:Enterovirus B, Human; D005260:Female; D007113:Immunity, Innate / Q000187:drug effects*; D009980:Influenza A virus; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control; D011761:Pyrrolidonecarboxylic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013290:Streptococcal Infections / Q000276:immunology / Q000517:prevention & control; D013292:Streptococcus agalactiae; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D053778:Thiazolidines; D014777:Virus Diseases / Q000276:immunology / Q000517:prevention & control*
D000276:Adjuvants, Immunologic; D013844:Thiazoles; D053778:Thiazolidines; C064893:pidotimod; D011761:Pyrrolidonecarboxylic Acid